EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

September 30, 2005

Conditions
Bronchial Asthma
Interventions
DRUG

beclomethasone dipropionate plus formoterol fumarate combination

DRUG

fluticasone propionate plus salmeterol xinafoate combination

Trial Locations (12)

Unknown

"Nzoz Non nocere", Gdansk

"Outpatients Department of Allergology Medcare", Gdansk

"Nzoz Krakow Poludnie Pulmonologic Policlinic", Krakow

Specialist Allergy Center All-Med, Krakow

Private Institute of Health and Beauty, Warsaw

"Dolnoslaski Centre of Medical Diagnostic Dolmed", Wroclaw

Kharkiv City Clinical Hospital 13 Pulmonological Department, Kharkiv

Institute of Phthisiology and Pulmonology, Academy of Medical Science of Ukraine, Depatment of Diagnostic, Therapy and Clinical Pharmacology of Lung Disease, Kiev

Republican Clinical Hospital Institute of Phthisiology and Pulmonology Academy of Medical Science of Ukraine, Clinical Functional Department, Kiev

Republican Clinical Hospital, Institute of Phthisiology and Pulmonology, Academy of Medical Science of Ukraine, Pulmonology Department, Kiev

Department of Hospital Therapy of Lugansk, State Medical Institute Lugansk, Regional Clinical Hospital, Luhansk

Department Therapy of Bronchopulmonary Pathology in Adults, Crimean Republic Research Institute of Physical Methods of Therapy and Medical Climatology, Yalta

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT00394368 - EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI | Biotech Hunter | Biotech Hunter